Variations in ACE, UCP2, TYMS, IL4, NFKB1, CASP8, TP53, HLAG, UGT1A1, and SGSM3 were linked to CRC risk and clinical characteristics, suggesting that this genetic marker panel could enhance clinical management. This evidence concerns the gene IL4 and colorectal carcinoma.